{"id":"las41008","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL2107333","moleculeType":"Small molecule","molecularWeight":"144.13"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting PDE4, the drug prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to elevated intracellular cAMP concentrations. This suppresses the activation and function of inflammatory cells, particularly T cells and dendritic cells, reducing the production of pro-inflammatory cytokines and chemokines. The mechanism is designed to provide anti-inflammatory and immunomodulatory effects for inflammatory and autoimmune conditions.","oneSentence":"LAS41008 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:18.248Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis"},{"name":"Atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT02955693","phase":"PHASE1","title":"Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2016-09","conditions":"Psoriasis","enrollment":32},{"nctId":"NCT01726933","phase":"PHASE3","title":"LAS41008 in Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2012-11","conditions":"Plaque Psoriasis","enrollment":839}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Verum"],"phase":"phase_3","status":"active","brandName":"LAS41008","genericName":"LAS41008","companyName":"Almirall, S.A.","companyId":"almirall-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LAS41008 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Psoriasis, Atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}